

**Amendments to the Claims**

Please cancel Claims 2-9 and 11. Please amend Claim 10. Please add new Claims 12-15. The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1. (Original) A medicament comprising a recombinant poxvirus which is genetically engineered to be incapable of expressing a native A41L protein, together with a pharmaceutical acceptable carrier for use in treatment or prophylaxis.

2-9. (Canceled)

10. (Currently amended) The medicament according to claim [[9]] 1, wherein the recombinant poxvirus is a genetically engineered vaccinia virus.

11. (Canceled)

12. (New) The medicament according to claim 1, wherein the recombinant poxvirus is a genetically engineered Modified Vaccinia Ankara (MVA) virus.

13. (New) The medicament according to claim 1, wherein the recombinant poxvirus is genetically engineered through deletion of nucleotide sequences encoding the native A41L protein.

14. (New) The medicament according to claim 13, wherein the nucleotide sequences are set forth in SEQ ID NO: 1.

15. (New) The medicament according to claim 1, which is incapable of expressing a chemokine-binding A41L protein.